Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
Because multiple myeloma (MM) is an incurable blood cancer, long-term survivors live with the possibility of relapse for their entire lives. As a long-term multiple myeloma survivor myself, I’ve made it my purpose to identify evidence-based cytotoxic MM therapies that I can take for the rest of my life. Curcumin, omega-3 fatty acids, resveratrol, vitamin D, others, vitamin C is one of those therapies.
To say that vitamin C is nutritionally beneficial is a gross understatement. Like other nutritionally beneficial foods and supplements however, the key is to determine bioavailablity, meaning how much of the nutrition actually gets into your blood stream.
Specifically, according to research, intravenous vit. C is cytotoxic to multiple myeloma because the intravenous delivery method, allows high enough serum concentrations of vit. C to kill MM cells.
MM patients frequently ask me if the other two delivery methods, oral and liposomal, provide high enough serum concentrations of asorbic acid, to also kill MM.
According to the study linked below, while liposomal vit. C is more bioavailable than oral vit. C, it is not as bioavailable as intravenous vitamin C.
Have you been diagnosed with multiple myeloma? Are you considering complementary MM therapies such as pharmacologically-dosed ascorbic acid? Scroll down the page, post a question or comment and I will reply to you ASAP.
“Vitamin C is one of the safest and most effective nutrients, experts say. It may not be the cure for the common cold (though it’s thought to help prevent more serious complications). But the benefits of vitamin C may include protection against immune system deficiencies, cardiovascular disease, prenatal health problems, eye disease, and even skin wrinkling.
A recent study published in Seminars in Preventive and Alternative Medicine that looked at over 100 studies over 10 years revealed a growing list of benefits of vitamin C…”
“A liposome is a spherical vesicle having at least one lipid bilayer. The liposome can be used as a vehicle for administration of nutrients and pharmaceutical drugs. Liposomes can be prepared by disrupting biological membranes (such as by sonication)…”
“Intravenous administration of vit. C has been shown to decrease oxidative stress and, in some instances, improve physiological function in adult humans. Oral vit. C administration is typically less effective than intravenous, due in part to inferior vitamin C bioavailability. The purpose of this study was to determine the efficacy of oral delivery of vit. C encapsulated in liposomes…
Research participants-All 11 of the enrolled research participants completed the study. The vit. C, irrespective of mode of delivery, was well tolerated, and there were no adverse events…
Plasma vit. C concentration- Plasma vitamin C concentrations were greatest following intravenous administration at all time points compared with each of the other modes of delivery (P < 0.001).
At two, three, and four hours, plasma vit. C concentrations were greater after oral administration of vit. C encapsulated in liposomes compared with placebo and unencapsulated vit. C (P < 0.01); and unencapsulated vit. C produced greater concentrations than placebo (P < 0.01)…
Advantages of liposomal encapsulation include accelerated intestinal absorption, increased stability of the pharmaceutical, protection of the gut from potentially irritating agents, and greater bioavailability of the pharmaceutical.18…
Noteworthy, in addition to its antioxidant properties, vit. C has multiple other beneficial physiological effects. These include:
We have demonstrated that oral delivery of vit. C encapsulated in liposomes promotes greater bioavailability than unencapsulated vit. C, while avoiding the risks associated with intravenous administration…”
“Our findings complement reported studies and further address the mechanism of action using clinical samples in which we observed that PAA killed tumor cells with high iron content, suggesting that iron might be the initiator of PAA cytotoxicity.
In addition, combination of PAA with standard therapeutic drugs, such as melphalan, may significantly reduce the dose of melphalan needed. This is beneficial because high doses of melphalan are very toxic not only to tumor cells but also to normal tissues, such as hematopoietic stem cell and epithelial cells in the gut (Shaw et al., 2014, Bayraktar et al., 2013).
The efficacy of high-dose melphalan by itself is clearly dose-dependent. Combined treatment of reduced dose melphalan with PAA achieved a significantly longer progression-free survival than the same dose of melphalan alone.
These data also suggest that the bone marrow suppression induced by high-dose melphalan can be ameliorated by the combination of PAA with lower dose of melphalan because of the lack of toxicity of PAA on normal cells with low iron content. It is important to consider for future clinical studies that renal insufficiency could be a contraindication for usage of PAA in MM patients…”